Abstract
This new strategic report from Espicom provides a comprehensive review of
current and future treatments for major blood cancer therapy areas: chronic
lymphocytic leukaemia, chronic myeloid leukaemia, acute myeloid leukaemia,
multiple myeloma and non-Hodgkin' s lymphoma.
- Unique market share and 5-year sales forecasts for leading products &
pipeline prospects
- A comprehensive examination of major blood cancer therapy areas
- Critical competitive evaluation and scoring of current and future products
THE REPORT COVERS MAJOR BLOOD CANCER AREAS
Chronic lymphocytic leukaemia Chronic myeloid leukaemia Acute myeloid
leukaemia Multiple myeloma Non-Hodgkin' s lymphoma
THE MARKET
Risk factors, how the disease affects patients, diagnosis and stages of the
disease The market in 2007 and 2012 Growth drivers and dampeners
PATIENT STATISTICS
Prevalence Diagnosis rates Unmet clinical need
CURRENT TREATMENT OPTIONS
Interventions by type Unique five point competitive assessment and scoring of
current therapies and companies involved 5-year sales forecasts for key
products
R&D: DRUGS IN LATE STAGE DEVELOPMENT
Focus on new classes of drugs and the companies involved Unique competitive
assessment and scoring of new therapies and companies involved 5-year sales
forecasts for key products from year of launch
Providing…
- Detailed analysis and 5-year forecasts for current leading products by
value
- A detailed review and assessment of up and coming products
- Unique product assessment and scoring
- An evaluation of the current understanding of blood cancers
View Cart
